Brief Summary: The objectives of the trial are to evaluate the safety and effectiveness of the FemaSeed Localized Directional Insemination for artificial insemination, now known as the FemaSeed Intratubal Insemination since FDA Cleared under K231730 in September 2023.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Confirmed pregnancy rate at approximately 3 weeks following FemaSeed procedure.
Timeframe: 3 weeks
Primary Safety: Occurrence of ectopic pregnancy per cycle
Timeframe: 7 weeks
Primary Safety: Occurrence of uterine perforation per cycle
Timeframe: At time of procedure